Traders Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of unusually large options trading on Tuesday. Traders bought 23,660 call options on the company. This represents an increase of 33% compared to the typical volume of 17,739 call options.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after buying an additional 1,436,550 shares during the period. State Street Corp boosted its stake in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Geode Capital Management LLC grew its position in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after purchasing an additional 622,602 shares in the last quarter. Norges Bank acquired a new stake in Boston Scientific during the 4th quarter valued at $2,199,395,000. Finally, Invesco Ltd. lifted its holdings in shares of Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after purchasing an additional 111,826 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Needham & Company LLC reduced their price objective on Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Royal Bank Of Canada cut their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Oppenheimer lowered their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. Robert W. Baird dropped their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, Stifel Nicolaus cut their price objective on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.43.

Boston Scientific Stock Performance

BSX stock opened at $74.26 on Wednesday. The company has a 50-day simple moving average of $92.36 and a 200 day simple moving average of $98.24. The company has a market capitalization of $110.09 billion, a P/E ratio of 38.28, a PEG ratio of 1.55 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific has a fifty-two week low of $73.92 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.